🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Fresenius looking to boost output after hurricane damage at rival Baxter

Published 10/08/2024, 09:11 AM
Updated 10/09/2024, 10:45 AM
© Reuters. FILE PHOTO: Fresenius headquarters in Bad Homburg near Frankfurt, Germany, February 27, 2018.    REUTERS/Ralph Orlowski/File Photo
FREG
-
BAX
-

FRANKFURT (Reuters) -Germany's Fresenius said it was checking options to speed up the start of new production lines of medical equipment at a North Carolina facility to help mitigate potential shortages from hurricane damage to rival Baxter (NYSE:BAX)'s site in the same state.

"We are working with the U.S. Food and Drug Administration’s Drug Shortage Staff, which is actively engaged with Baxter and other manufacturers" to assess whether and by how much capacity has to be increased, Fresenius said in a statement.

The Germany-based healthcare group said its generic hospital drugs unit Fresenius Kabi had recently started manufacturing intravenous (IV) solutions at a new facility in Wilson, North Carolina, and that it was checking options to start up more production lines faster than planned in the unaffected location.

"Such a ramp-up of U.S. production at our Wilson site would take several months and would not be sufficient to make up for a prolonged loss of production by Baxter," the German company added.

U.S. Senator Amy Klobuchar on Tuesday urged the Department of Health and Human Services to address the shortage "as quickly and safely as possible" and coordinate with the Federal Trade Commission and Department of Justice to prevent the distribution of counterfeit IV solutions.

Hurricane Helene slammed into the Florida Gulf coast in late September, ripping up roads, tossing homes about and severing lines of communication through southeastern U.S. states. In its wake, hundreds of people were unaccounted for and many confirmed dead.

On Sept. 29, medical device maker Baxter said its North Cove site had been affected by hurricane-related flooding and was closed for production. It said it was working with the government to assess the damage and bring the plant back online as quickly as possible.

© Reuters. FILE PHOTO: Fresenius headquarters in Bad Homburg near Frankfurt, Germany, February 27, 2018.    REUTERS/Ralph Orlowski/File Photo

Baxter said in a statement on Monday it was working with government agencies, including the U.S. Food and Drug Administration, on special importation requirements for certain sites and products located outside the United States.

"We have moved finished goods from our North Cove site that were not impacted by the storm and are inspecting other finished goods onsite. This inventory will be used to support current allocations in the short term," Baxter said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.